Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc. Ushering in a new era for treating diseases with high unmet needs

04/29/2026

Post-bariatric hypoglycemia (PBH) is a rare, chronic condition with no FDA-approved treatments. Among the roughly two million people who have had Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy in the past decade in the U.S., an estimated 160,000 are living with PBH today.

The condition can cause debilitating low blood sugar episodes when the brain does not receive enough glucose. PBH can be difficult to diagnose as symptoms, such as brain fog, fatigue, sweating, blurred vision, and dizziness, can be non-specific, vary in severity, and/or be mistaken for dumping syndrome. Learn more about PBH on our website at https://bit.ly/4cCeodq

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about one of our five core values guiding...
04/24/2026

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about one of our five core values guiding Rob Chang and the rest of below.

This week, is at the American Association of Clinical Endocrinology’s (AACE) Annual Meeting in Las Vegas. More details...
04/22/2026

This week, is at the American Association of Clinical Endocrinology’s (AACE) Annual Meeting in Las Vegas. More details below. We hope to see you there!

04/17/2026

After Maggie was diagnosed with post-bariatric hypoglycemia (PBH), she had trouble finding answers for living with this condition, adding another difficult layer to managing her often debilitating symptoms.

We created the “Understanding PBH” guide to provide education, support, and a sense of connection for the PBH community. Learn more about PBH through Maggie’s story and explore the guide here: https://bit.ly/4cid8vP

We have an audacious mission to develop novel therapies for high unmet needs. Where others see challenges, we see opport...
04/13/2026

We have an audacious mission to develop novel therapies for high unmet needs. Where others see challenges, we see opportunities that members of like Kelly Fox pursue with urgency and unwavering commitment to the communities we serve.

If you’re looking to do meaningful work with purpose, we’re currently hiring across a number of roles.

Explore opportunities: https://bit.ly/48Maa0i

ALS affects as many as 30,000 adults in the U.S. and 3,000 in Canada. The most common form of the disease is sporadic AL...
03/31/2026

ALS affects as many as 30,000 adults in the U.S. and 3,000 in Canada. The most common form of the disease is sporadic ALS, with more than 90% of people with ALS showing no clear family history. Learn more about ALS on our website at https://bit.ly/4sIuXtH

03/26/2026

Maria was told she wouldn’t survive another year without bariatric surgery. The procedure saved her life, but a new challenge emerged: post-bariatric hypoglycemia ( ).

At Amylyx, we’re committed to listening to and learning from those living with PBH. In this clip, Maria and her daughter Kelly reflect on the highs and lows of her journey and the hope for treatment. Watch Maria’s full story here: https://bit.ly/4c8TlPe

03/24/2026

We’re pleased to announce the completion of enrollment in our pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia (PBH).

Thank you to the LUCIDITY trial sites and participants for their study contributions and commitment to driving innovation!

We look forward to topline data from the trial, which is expected in Q3 2026. See today’s press release for more information: https://bit.ly/4btlG2z

03/20/2026

Wolfram syndrome is a rare genetic disorder that affects multiple organs and systems over time.

Most people with Wolfram syndrome have mutations in the WFS1 gene, which encodes wolframin, a protein essential for maintaining endoplasmic reticulum (ER) homeostasis and normal cellular function.

When wolframin is impaired, cells experience chronic ER stress and mitochondrial dysfunction. Learn more about Wolfram syndrome on our website at https://bit.ly/3NQQ3H5

This week, is at Muscular Dystrophy Association's Clinical and Scientific Conference, where we’re presenting an update...
03/09/2026

This week, is at Muscular Dystrophy Association's Clinical and Scientific Conference, where we’re presenting an update on our Phase 1 LUMINA trial in . More details below.

02/27/2026

Ahead of tomorrow, Amylyx honors the resilience of those living with rare diseases and the communities that stand beside them. At our recent Anchor Week, we gathered for a Rare Night Out to recognize our shared purpose and participated in Rare Disease Trivia to promote awareness and connection.

Happy Amylyx Anniversary to Jim Frates, Dan Sitte, Jenny Tavares, and Eric Cooksey! At this month’s Anchor Week, we cele...
02/24/2026

Happy Amylyx Anniversary to Jim Frates, Dan Sitte, Jenny Tavares, and Eric Cooksey! At this month’s Anchor Week, we celebrated the many contributions they’ve made the past 5 years and thanked them for their unwavering commitment to developing novel therapies for communities with high unmet needs.

Address

55 Cambridge Parkway, Suite 6W
Cambridge, MA
02142

Website

https://www.amylyx.com/social-media-guidelines, https://www.amylyx.com/privacy-notice

Alerts

Be the first to know and let us send you an email when Amylyx Pharmaceuticals Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Amylyx Pharmaceuticals Inc.:

Shortcuts

Share